glp 1 news Science's 2023 Breakthrough: GLP-1 Agonists Show Promise Against Obesity-Associated Disease GLP-1 weight loss drugs leave

What matters most is that the prescribing clinician has experience managing obesity as a chronic disease and can follow you over time

This is especially important considering the increasing use of these medications. The authors write that, to their knowledge, this is the first case detailing a patient developing this serious condition after starting tirzepatide for diabetes (in contrast to those treated with tirzepatide for weight loss)

She likens the phenomenon to insulin resistance, which is still not fully understood decades after its discovery

The field of GLP-1 medications continues to evolve rapidly

While formulations differ in dosing frequency, onset, and tolerability, they show broadly comparable safety and efficacy

GLP-1 receptor agonists are primarily used to treat type 2 diabetes by lowering blood sugar and reducing food intake